DNDi Southern Africa (joint office with GARDP)

DNDi Southern Africa (joint office with GARDP)

The joint office for Southern Africa for DNDi and the Global Antibiotic R&D Partnership (GARDP) was opened in November 2017.

DNDi projects

Joint office Southern Africa – for DNDi & GARDP

Brickfield Canvas, Unit 12, 1st Floor
35 Brickfield Road
Woodstock
Cape Town 7195
South Africa

dndi-gardp-southafrica@dndi.org

Highlights

2019

  • R&D: Prepared GARDP Phase III study for gonorrhoea and Phase II for neonatal and paediatric sepsis, both due to start enrolment in 2020
  • Partnerships: Supported stakeholder efforts to advance treatment access for cryptococcal meningitis with DNDi, and coordinated with research partners for GARDP studies

2018

  • Continued to strengthen its collaborative efforts with the South African Medical Research Council (SAMRC). SAMRC provided 4 million Rand (~240,000 EUR) to further GARDP’s activities in South Africa to deliver affordable, new or improved antibiotic treatments for drug-resistant bacterial infections, beginning with neonatal sepsis and sexually-transmitted infections.
  • Supported GARDP‘s launch of a global observational study of babies with sepsis, with three South African sites, to guide development of new and improved antibiotic treatments for newborns.
  • Recruited a locally based team to provide support to the launch and execution of clinical trials in South Africa

2017

  • Opening of a new DNDi-GARDP joint office in Cape Town
  • Collaboration agreement with South African Medical Research Council